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Abstract
Background: Src and signaling molecules downstream of Src, including signal transducer and activator of transcription 3
(Stat3) and cMyc, have been implicated in the development, maintenance and/or progression of several types of human
cancers, including breast cancer. Here we report the ability of siRNA-mediated Src knock-down alone, and simultaneous
knock-down of Src and Stat3 and/or cMyc to inhibit the neoplastic phenotype of a highly metastatic human model breast
cancer cell line, MDA-MB-435S, a widely used model for breast cancer research.
Methodology/Results: Src and its downstream signaling partners were specifically targeted and knocked-down using
siRNA. Changes in the growth properties of the cultured cancer cells/tumors were documented using assays that included
anchorage-dependent and -independent (in soft agar) cell growth, apoptosis, and both primary and metastatic tumor
growth in the mouse tumor model. siRNA-mediated Src knock-down alone, and simultaneous knock-down of Src and Stat3
and/or cMyc inhibited the neoplastic phenotype of a highly metastatic human model breast cancer cell line, MDA-MB-435S.
This knock-down resulted in reduced growth in monolayer and soft agar cultures, and a reduced ability to form primary
tumors in NOD/SCID mice. In addition, direct intra-tumoral injection of siRNAs targeting these signaling molecules resulted
in a substantial inhibition of tumor metastases as well as of primary tumor growth. Simultaneous knock-down of Src and
Stat3, and/or Myc exhibited the greatest effects resulting in substantial inhibition of primary tumor growth and metastasis.
Conclusions/Significance: These findings demonstrate the effectiveness of simultaneous targeting of Src and the
downstream signaling partners Stat3 and/or cMyc to inhibit the growth and oncogenic properties of a human cancer cell
line. This knowledge may be very useful in the development of future therapeutic approaches involving targeting of specific
genes products involved in tumor growth and metastasis.
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Introduction
Human breast cancer results from a combination of events and
changes that alter the growth properties of breast epithelial cells.
Some of these changes have been characterized to provide a clear
contribution to the development and/or progression of the cancer
and include overexpression of HER2/neu in about 20% of breast
cancer [1], and hereditary mutations in BRCA1 or BRCA2 in
approximately 5% of breast cancers [2]. Other alterations are less
well defined in terms of their contribution to the final neoplastic
phenotype, and include activation of Src, which has been shown in
up to 30–70% of breast cancers by our lab and others [3–5].
Src is a non-receptor tyrosine kinase that can cause cellular
transformation in cell culture and tumor formation in animals if its
activitybecomeselevated.Src’seffects arethoughtto bemediated by
activation of downstream signaling pathways including the mitogen-
activated protein kinase (MAPK), the phosphatidylinositol 3-kinase
(PI3K), and the signal transducer and activator of transcription 3
(STAT3) pathways (Fig. 1). Therefore, Src acts as a master control
element, regulating many aspects of oncogenesis, sinceSrcactivation
of these and other pathways can stimulate cell proliferation, motility,
angiogenesis, invasion, and metastasis [6–8]. Src activity is elevated
in several types of human cancers, including cancers of the breast,
colon, ovary, prostate, and pancreas [3,4,9–12] and in melanomas
[13]. In some breast cancer models, inhibition of Src activity
suppresses the transformed phenotype of breast cancer cell lines [14]
and restores tamoxifen sensitivity to tamoxifen-resistant breast
cancer celllines[15], suggesting itmay be a useful target for therapy.
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pathways might play a role in human breast cancer and whether
targeting these pathways for suppression using short interfering
RNA (siRNA) might have value as a future therapeutic. It was felt
that Src was a good candidate for knock-down because: 1)
elevation of Src activity has been implicated in the development
and/or progression of human cancer, 2) efficient knock-down of
Src is unlikely to cause impairment of normal cells, as Src
knockout mice are viable [16]; and 3) it is unlikely that complete
knock-down of Src would be required to elicit a cellular effect on
cancer cells, as low levels of Src activity are present in most normal
cell types.
As a model system, we chose to examine MDA-MB-435S, a
highly metastatic cancer cell line that we previously had shown to
possess high Src activity [3,17,18]. This cell line has been utilized
in over 780 scientific papers as a model breast cancer cell line, but
some controversy has arisen in the literature over the last few years
regarding its classification [19–21], as it possesses some melano-
cytic characteristics. More recently, considerable evidence has
been provided by several laboratories supporting the breast cancer
origin of these cells [22,23] as well as the classification of the
MDA-MB-435S cells into the basal subset of human breast
cancers that often express melanocyte-related genes [24,25]. The
MDA-MB-435S cells have also been characterized to fall within
the claudin-low subtype of breast cancer cells which are enriched
in epithelial-to-mesenchymal transition and stem-cell like features
[26]. The basal subtype of human breast cancer is typically triple-
negative (estrogen receptor, progesterone receptor, and HER2/
neu negative), and as a consequence has a poor prognosis, as it is
most often poorly responsive to many of the current treatment
strategies [27]. Basal subtype tumors can also be particularly
aggressive, and often more likely to recur than other subtypes of
breast cancer. Therefore, it is very important that we develop
alternate methods of treatment that target this particular subtype
of cancer.
Cancer therapies targeting specific proteins are relatively new,
and include antibodies (eg. Herceptin against HER2/neu),
chemical inhibitors (Imatinib against Bcr/Abl), and now, siRNA.
As compared to inhibitors targeting the protein products of various
genes, siRNA shifts the focus of the targeting strategy from the
protein that contributes to the malignancy to the mRNA that
produces the protein. This is made possible by the use of siRNAs
and their utilization of the RNA interference (RNAi) pathway to
degrade specific cellular mRNAs [28,29], thereby modifying
protein expression levels and activities. This strategy provides
the opportunity to pick key genes in the malignant process
irrespective of whether it may be difficult to develop traditional
pharmaceutical agents that target these proteins (ie. transcription
factors such as Stat3). siRNAs also possess additional features
which make them highly attractive as pharmaceuticals, including
1) their high degree of specificity, 2) the ease with which multiple
siRNAs targeting a single proteins can be designed, thereby
reducing the likelihood of drug resistance, and 3) the ability to
simultaneously target two or more gene products. siRNAs are
introduced into cultured cells directly by transfection or by
utilizing plasmid or viral vectors, and similar techniques have been
utilized in whole animals, where ‘‘naked’’ siRNA can be delivered
to tissues/organs to treat certain disease conditions [30]. In
humans, the administration of siRNA using various carrier
molecules is in its early stages of testing, but promising early
results have been obtained. With perhaps the greatest relevance to
cancer treatment, investigators have now begun phase I clinical
trials involving the systemic administration of siRNA (in targeted
nanoparticles) to patients with solid cancers [31]. Their data
demonstrate that the siRNA is delivered to the tumors and is
capable of knocking down specific mRNAs, which is very
encouraging news for laboratories currently developing siRNA-
based therapeutics for human cancers.
We wished to test the feasibility of the direct application of
siRNA complexed with lipids for the knock-down of Src, whose
role in the maintenance of the complex phenotype of cancer is not
clearly understood. It also seemed relevant to examine the effect of
inhibiting more than a single signal transducer in the Src signaling
pathway, or interacting pathways, through the use of other
siRNAs in combination with Src siRNA. Direct application of
siRNA avoids the use of viral-based vectors whose safety when
used in humans is often currently under question. In this report,
Src knock-down in combination with the knock-down of the
downstream molecules STAT3 or cMyc is shown to result in a
strong inhibition of the anchorage-independent growth, tumor
growth, and metastasis of a human cancer cell line.
Results
siRNA targeting Src knocks down protein expression and
affects the anchorage-independent growth of MDA-MB-
435S cells
Of the several siRNAs targeting Src that were designed and
tested, the most effective one was used to knock down Src in the
highly metastatic human breast cancer cell line MDA-MB-435S
[17], a cell line in which Src activity is elevated [3] and potentially
playing an important role in maintaining its neoplastic phenotype.
Src siRNA caused a 62 or 67% reduction, respectively, in Src
protein levels relative to either untransfected cells or cells
transfected with a non-targeting control siRNA (significant
differences with p,0.05; see methods and fig. legends for
description of statistics for each figure) (Fig. 2A). The non-
targeting control siRNA caused no significant change in Src levels
relative to untrasnfected cells. This reduction by Src siRNA was
accompanied by a corresponding reduction in Src kinase activity.
The inhibitory effects typically lasted 4–5 days in rapidly dividing
cells in culture (results not shown), and this duration was sufficient
to carry out cell culture growth experiments. We noted that
siRNAs targeting other gene products often resulted in 90–95%
decreases in protein levels (see Fig. 3), suggesting that the relatively
long (approximately 12–18 hrs) half-life of the cellular Src protein
[32] may play a role in the effectiveness of the several Src siRNA
we tested, which typically gave reductions of 50–80% (results not
shown). In slowly growing cells and ‘‘in vivo’’, siRNA silencing can
Figure 1. Src and some of the signaling pathways downstream
of Src. Src regulates several downstream signaling pathways including
the STAT3 pathway, the PI3K pathway, and the MAPK pathway.
doi:10.1371/journal.pone.0019309.g001
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and [33]).
Src siRNA was examined for its ability to alter certain growth
characteristics of these tumor cells. The ability to suppress
anchorage-independent growth in soft agar, a characteristic of
transformed or cancer cells that is highly correlated with
tumorigenicity [34], was initially examined. The Src siRNA was
able to reduce the number of colonies in soft agar by 61% and
53% relative to either oligofectamine alone or negative controls
siRNA treated cells, respectively (Fig. 2B). Treatment with Src
siRNA also affected anchorage-dependent growth and resulted in
a 50% reduction in cell number in comparison to untreated cells 5
days post transfection (Fig. 2C).
Src knock-down combined with knock-down of STAT3 or
cMyc augments the effects on anchorage-independent
and -dependent growth
The cell growth effects of Src siRNA alone were further
examined to see if they could be augmented by combining the Src
siRNA with siRNAs that target signaling pathways that are either
downstream of Src or that interact with the Src signal transduction
cascade. siRNAs targeting proteins in several signaling pathways
including MAPK1, Akt1, cMyc, and STAT3 were examined for
their ability to modify cell growth.
These siRNAs were initially examined for their ability to reduce
their corresponding target proteins. Western blots demonstrated
that these siRNAs could significantly reduce protein expression
levels of their corresponding proteins (Fig. 3A). Several (2–4) target
sequences in each targeted protein were tested for gene
knockdown, and the most potent sequence was selected for further
use (results not shown). The effects of the siRNAs appeared specific
to their targeted protein. The degree of reduction varied
somewhat between the different siRNAs, but these siRNAs were
capable of reducing protein levels by 60–95% (quantitated blots,
results not shown). Akt2 or EGFR proteins were undetectable in
this cell line.
MDA-MB-435S cells were transfected with a single siRNA or
various siRNAs in combination with Src siRNA and the effects on
growth in soft agar were examined. In contrast to the experimental
protocols utilized in previous figures, the cells were transfected
only once, which resulted in slightly lower transfection efficiencies
and slightly lowered growth effects, but simplified the procedure
and reduced the usage of siRNA reagents. Of the siRNAs tested,
those targeting Src, STAT3, and cMyc were among the most
effective in inhibiting anchorage-independent colony formation in
soft agar relative to the control siRNA group. Src siRNA caused a
35% reduction, and Stat and cMyc caused reductions of 38% and
35%, respectively, under these conditions (Fig. 3B and C). Akt1
appeared to have little or no effect on growth in soft agar.
However, simultaneous targeting of Src and STAT3, or Src and
cMyc produced a much greater effect, resulting in a 65–70%
reduction in colony number relative to control siRNA, and this
exceeded the inhibitory effects observed with any single siRNA
(significant differences between single siRNA treatments and dual
siRNA treatments).
The ability of the siRNAs individually and in combination with
Src siRNA to cause changes in cell growth in monolayer culture
was examined. When the cells were treated with the different
individual siRNAs, it was observed that the Src, MAPK1, Akt1,
STAT3, and cMyc siRNA reduced the cell number relative to
control siRNA-treated cells by 20% to 40%, while siRNAs for
Akt2 and EGFR did not exhibit significant effects on monolayer
cell growth (Fig. 3D). When Src siRNA was combined with the
other siRNAs, additional reductions in growth over the single
Figure 2. Src siRNA causes reductions in Src protein and
activity and inhibits cell growth. MDA-MB-435S cells were left
untreated or transfected with control or Src siRNA. 24 hours later, some
cells were plated into soft agar or tissue culture dishes. After 48 hours,
the remainder of the cells were processed for Src immunoblots or Src
kinase activity. The results from the immunoblot and kinase assay were
quantitated, the results are shown, and significant differences are
indicated (* and **; p,0.05) (A). The cells in soft agar were grown for
14 days and colonies were quantitated (B) with significant differences
indicated (*; p,0.05). The cells in monolayers were quantitated 5 days
after plating and the significant differences indicated (*; p,0.01)
(C). Each data point is the mean of duplicate (western and kinase)
or triplicate (soft agar and monolayer) samples +/21 S.D. and is
representative of at least 3 independent experiments.
doi:10.1371/journal.pone.0019309.g002
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MDA-MB-435S cells were transfected with siRNA, and 24 hrs post transfection, cells were plated into soft agar or into tissue culture dishes. Cells to be
analyzed by immunoblotting were lysed 60 hrs post-transfection and duplicate samples of each cell extract were analyzed (A). The cells in soft agar were
grown for 14 days (B) and colonies larger than approximately 50 cells were quantitated (C). The cells in monolayer culture were quantitated 4 days after
plating (D). Each growth condition was assayed in triplicate and is representative of at least 3 independent experiments. In C and D, comparisons were
made between the group treated with control siRNA and various single targeting siRNA, and statistically significant differences are noted (*; p,0.05). In C
and D, comparisons between singly and multiply transfected cells are made, and significant differences are noted (**; p,0.05).
doi:10.1371/journal.pone.0019309.g003
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observed (40–50% reduction in cell number relative to control
siRNA-treated plates) (Src and Stat3 combined were significantly
different than either Src or Stat3 alone; but the differences
between Myc alone and Myc combined with Src or Stat3 or both,
were not).
Src and STAT3 knock-down reduce tumor formation in
NOD/SCID mice
siRNA treatment of the MDA-MB-435S cells was examined to
determine if it would affect their ability to form tumors in NOD/
SCID mice. Our laboratory (results not shown) and others have
previously shown that MDA-MB-435 cells form primary tumors
when implanted either subcutaneously on the back or into the
mammary fat pad of mice and metastasize to sites such as the
lymph nodes and lungs [18,35,36]. To facilitate the identification
of the implanted tumor cells, cells that stably expressed GFP
protein were utilized. siRNA transfected cells (control or
Src+STAT3 siRNA) were implanted into the mammary fat pad
(4 mice/group) and the mice were observed for development of
palpable tumors at the site of implantation.
On day 66, the mice were euthanized and examined. Primary
tumors were observed at the site of implantation. The tumors were
excised and weighed. The average weight of the tumors from the
control siRNA mice was 0.167 g, compared to 0.080 g in the
Src+STAT3 siRNA group (Fig. 4A). Microscopic examination
detected the presence of cancer cells in the tumor (Fig. 4B) and the
presence of the MDA-MB-435S cells was confirmed by immuno-
staining (Fig. 4C) and immunoblotting (Fig. 4D) for GFP. These
results demonstrated that transfection with Src+STAT3 siRNA
was able to significantly reduce but not eliminate the ability of the
cells to form tumors in the mice.
We then sought to determine whether siRNA might be able to
suppress the long-term post-implantation growth of tumor cells
through experiments involving direct intra-tumoral injection of
siRNAs. MDA-MB-435S cells were implanted into the mammary
fat pad, and starting two days post-implantation, the mice were
treated with control, Src+STAT3, or Src+STAT3+Myc siRNA.
siRNA complexed with lipid-based transfection reagents have
previously been show to be effective at delivering siRNA to cells in
whole animal models [37] and results from our laboratory
(unpublished observation) showed an approximately 30% reduc-
tion in luciferase signal following a single injection of lipid-
complexed luciferase siRNA into a 3 mm diameter luciferase-
expressing tumor. After allowing the tumors to grow to
approximately 6–7 mm in diameter (day 47 post-implantation),
Figure 4. Src+STAT3 siRNA reduces tumor formation in NOD/SCID mice. 1610
6 cells transfected with control (mice 1–4) or Src+STAT3
siRNAs (mice 5–8) were implanted into the mammary fat pad of mice. After 66 days, the tumors were excised and weighed (significant differences are
indicated (*; p,0.05)(A). Sections of the tumor were stained (B) or subjected to immunostaining with anti-GFP antibody (C). Malignant cells are
indicated by an arrow. A portion of each tumor was homogenized with RIPA buffer and immunoblotted with anti-GFP antibodies (D).
doi:10.1371/journal.pone.0019309.g004
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injections of Src+STAT3 siRNA. Between 80 days up until the
end of the experiment, the control group showed more rapid
tumor growth than the other 3 injection groups, and had the
largest average tumor size of 3899 mm
3 (Fig. 5A). The other 3
groups, including mice changed from control to Src+STAT3
siRNA, the Src+STAT3 group, and the Src+STAT3+Myc group
had smaller average tumor sizes of 892, 878, and 610 mm
3,
respectively. The experiment was ended on day 126, the tumors
were examined, and weighed (Fig. 5B and C). The control group
had the largest average tumor weight (1.78 g), followed by the
group that received control siRNA before receiving Src+STAT3
siRNA (0.96 g), the Src+STAT3 group (0.52 g), and the
Src+STAT3+Myc group (0.41 g), and these measurements agreed
well with the tumor size measurements. These results demonstrat-
ed that siRNA is capable of inhibiting tumor growth locally when
injected into the site of the tumor in whole animal models. They
also illustrate a potentially useful method to increase the
effectiveness of siRNAs to elicit cellular effects through the use
of combinations of siRNAs to target key components of one or
more signaling pathways.
Inhibition of tumor metastasis
Partial dissection of each mouse was performed to examine for
the presence of tumor metastases, followed by microscopic
examination for the presence of tumor cells. Representative
microscopic views of the lung and liver are shown in Fig. 6A, and
summarized results from the combined gross and microscopic
examination in Fig. 6B. 4 of 5 mice in the control group had
metastatic tumor infiltration in various organs, including the lung,
liver, stomach, and intestine. Three mice in this group had grossly-
visible tumors, including two with abdominal tumors and one with
tumor nodules in the lungs. 3 of 5 mice in the group changed from
control to Src+STAT3 siRNA had metastases that were detectable
only after microscopic examination of the lung and liver. Grossly-
and microscopically-visible metastasis developed in the lung of
only 1 of 5 mice in the Src+STAT3 group and in none of the 5
mice in the Src+STAT3+Myc group. These results show that
knock-down of Src and STAT3 can reduce the appearance of
metastasis and suggest that not only are Src and STAT3 important
in the growth of the primary tumor, but may have a role in the
metastatic process.
Src and STAT3 siRNA induce apoptosis in treated cells
The siRNAs may have affected cell growth through one or
several mechanisms, including the stimulation of apoptosis, and
this particular possibility was assessed using the TUNEL assay
(Fig. 7). Staurosporine, a potent pro-apoptotic agent, caused an
increase in apoptotic cells (upper panel, dotted line) compared to
control cells (solid line), as evidenced by an increased incorpora-
tion of fluorescein-labeled dUTP into DNA of the treated cell
population (rightward shift of curve). Src siRNA was also found to
cause increased apoptosis in the MDA-MB-435S cells, (upper
panel, dashed line), as compared to control cells (solid line).
STAT3 siRNA caused a smaller, but significant shift in the cell
population (middle panel). Myc siRNA caused no significant
change. Combining Src plus STAT3 siRNA (lower panel, dotted
line) did not increase TUNEL staining over that seen with Src
siRNA alone.
Discussion
Our results indicate that knock-down of Src, and its down-
stream signaling partners STAT3 and cMyc, using siRNA in the
human cancer cell line MDA-MB-435S, have a dramatic effect on
its neoplastic properties. Importantly, in a mouse model, the
siRNA treatments were highly successful at reducing the formation
of tumor metastasis, and this was accompanied by reduced growth
of the primary tumor. This is of particular interest, because
currently, metastatic forms of human malignancies are particularly
difficult to treat. In addition, MDA-MB-435S is a triple-negative
cell line (estrogen receptor, progesterone receptor and HER2
negative) that belongs to the basal type of breast cancers [38], and
that are typically unresponsive to receptor-targeted treatments.
Our results indicate that knock-down of Src using siRNA in the
MDA-MB-435S cells has a significant effect on the anchorage-
independent growth characteristics of the cells, an important
hallmark of cell transformation, and to a lesser extent, reduced the
growth rate in monolayer cultures. Src is upstream of several
important pathways that have been implicated in the neoplastic
phenotype [39], and it is likely that targeting Src for knock-down
also has effects on these downstream signaling pathways, including
the Ras/MAPK, AKT/PKB, and STAT3/Myc pathways. The
suppression of anchorage-independent growth was substantial but
not complete. This probably reflects the complex nature of the
transforming defect that is present as well as our inability to fully
suppress Src activity. siRNAs against other single targets, including
STAT3 and cMyc, also demonstrated similar abilities to inhibit
anchorage-independent growth. STAT3 and cMyc are down-
stream mediators of Src (see Fig. 2), and as such, might be
expected to show somewhat similar inhibitory patterns as Src.
Because the effects of the siRNAs on anchorage-independent
growth seemed to correlate with their effects on tumor growth in
our mouse model, this suggests that growth in soft agar might be
an effective method of screening the responsiveness of cells to
larger/different panels of siRNAs.
Targeting two or more growth signaling molecules may serve to
inhibit multiple parallel pathways which are collectively important
for cell growth or may inhibit a single pathway more efficiently by
suppressing more than one mediator along the pathway. This
second mechanism may be of particular relevance where siRNA-
mediated protein knock-down is not 100% efficient, which is
common when utilizing siRNAs. It may be easier and/or more
effective to knock-down two or more genes that lie along the same
pathway for an additive effect than to attempt to suppress the
pathway by targeting a single gene product.
Most of the effects we observed upon cell growth when
combining siRNAs were additive or less than additive under the
limited number of growth conditions tested here. Additive
inhibition can occur within the same pathway or in parallel
pathways, and the literature supports the likelihood that a
significant component of the inhibition we observed with Src,
Stat3, and Myc comes from inhibiting this single pathway (see
Fig. 1). Based upon our understanding that there are likely
multiple positive signaling inputs (signaling pathway crosstalk)
along the Src, Stat3, Myc pathway (eg. Stat3 can also be activated
by Jak2 in addition to Src), it seems desirable to suppress the
pathway at multiple levels to achieve a maximal effect under a
variety of cellular conditions.
Combining two or more siRNAs has the potential to greatly
expand the biological potency of RNAi. It has the major
advantage over single protein targeting strategies that if single
protein knock-down doesn’t give the desired response, combina-
tions of proteins can be targeted. Libraries of RNAi reagents are
currently available and screening methods allow the examination
of many different combinations of siRNAs. Delivery of multiple
siRNAs is no different than that for single siRNAs, and many of
the complex ‘‘in vivo’’ drug interactions that occur between
Inhibition of Tumor Growth Using siRNA
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facilitating their future use in humans.
In the mouse tumor models, cells pretreated with Src and
STAT3 siRNA by transfection or treated by direct injection of
siRNA into the tumor showed a strong reduction in the ability to
form primary tumors. No overt toxic effects of the siRNA
injections were observed using the dosages utilized in this study. It
is possible that higher dosages of siRNA may be more efficacious.
Further improvements in technology and in the stability of siRNA
are also likely to make this approach more efficient. In addition, it
was noted that siRNA injections into the primary tumor have a
major effect to inhibit the development of distant metastasis in
organs such as the lung and liver. In our experiments, this was
most evident in the group of mice treated with Src+STAT3+Myc
siRNAs, where there was complete blockage of metastasis. Because
the primary tumors were significantly smaller in the treatment vs
control group, it is possible that at least part of this effect may be
due to a reduction in the malignant cell number of the primary
tumor, with a corresponding reduction in the likelihood of tumor
spread. Alternatively, it is possible that Src+STAT3 siRNA or
Src+STAT3+Myc may cause changes in the invasive properties of
the cells in the environment of the primary tumor that reduces
their metastatic potential. Src is known to promote metastasis
through its effects on vascular endothelial growth factor synthesis
[40], angiogenesis [7,41], production of metalloproteases [42], cell
adhesion [43], and cell motility [44]. In this regard, our lab has
demonstrated that Src promotes the destabilization of the Von
Hippel-Lindau tumor suppressor protein that negatively regulates
vascular endothelial growth factor synthesis [45]. STAT3 and
cMyc have also been implicated in both primary tumor growth as
well as tumor metastasis [46–48]. There is also a more remote
possibility that the siRNA spread beyond the primary tumor to
affect metastatic cells at remote sites.
RNAi is an important tool for the study of signaling pathways as
well as a potential therapeutic agent for the suppression of
aberrantly expressed and/or mutated gene products as are often
found in human cancers. siRNA and short-hairpin RNA targeted
against oncogenes such as K-RAS
V12 [49], Twist [50], and others
can suppress the neoplastic phenotype of cancer cells. RNAi has
been demonstrated to be more effective than other gene targeting
approaches such as anti-sense RNA and anti-sense oligonucleo-
tides [51,52], and studies utilizing direct intravenous application of
siRNA to target genes such as FAS for the treatment of fulminant
hepatitis [53] support the usefulness of direct application of siRNA
to control the expression of target proteins in cancer and other
diseases. The functional stability of conventional siRNAs in whole
animals has been reported to span at least 14–21 days [33] and the
introduction of chemical modifications such as 29-O methyl groups
may extend the duration of their effectiveness [54]. It will be
important to examine alternate modes of delivery, as many
naturally-occurring tumors are not readily accessible. Along this
line, we and others are investigating delivery vehicles that would
allow targeted delivery of siRNA, such as cell-targeting peptides
incorporated into siRNA-containing nanoparticles. Once methods
of delivery into whole organisms are perfected, siRNA could prove
a powerful adjunct and/or substitute for current treatment
protocols for several diseases, including many forms of cancer.
Materials and Methods
Ethics Statement
All animals used in this study were housed and received care
according to the University of Calgary Animal Care Committee
guidelines. Prior to commencement of this study, procedures were
reviewed and approved by the University of Calgary Animal Care
Committee, Protocol M07108, and are in accordance with the
principles outlined in ‘‘The Guide to the Care and Use of
Experimental Animals’’ by the Canadian Council on Animal
Care.
siRNA molecules
RNA for the Src, STAT3, cMyc, and control siRNA was
synthesized by the University of Calgary Core DNA/RNA facility
(Dr. R. Pon) and annealed in RNA buffer (6 mM Hepes pH 7.5,
20 mM KCl, and 0.2 mM MgCl2) to form double stranded siRNA
(20 mM) with 39 2 nucleotide dTdT or UU overhangs. Several
siRNAs were screened for each protein targeted and the siRNA
giving the best knockdown was chosen for use. The control siRNA
target sequence was AATTCTCCGAACGTGTCACGT. The
Src siRNA target sequence was TGTTCGGAGGCTTCAA-
CTCCT. The cMyc siRNA target sequences were GCTTCAC-
CAACAGGAACTA, AAACATCATCATCCAGGAC, CCT-
GAGCAATCACCTATGA, AACGATTCCTTCTAACAGA,
and ACGACGAGACCTTCATCAA (siRNA mixed in equimolar
amounts). The STAT3 siRNA target sequence was GGCG-
TCCAGTTCACTACTA. siRNAs targeting Akt1, Akt2, the
epidermal growth factor receptor (EGFR), and MAPK1 were
Smartpools from Upstate Biotech. Inc (New York, USA).
Antibodies
A hybridoma producing MAb327 anti-Src antibody [55] was a
kind gift from J. Brugge. Ab-1 anti-a-tubulin antibody was from
Oncogene Research Products. Anti-green fluorescent protein
(GFP) antibody was from Santa Cruz (California, USA).
Antibodies against MAPK, cMyc, STAT3, Akt1, and Akt2 were
from Upstate Biotech. Inc. H9B4 antibody against the EGFR has
been previously described [56].
Transfection of Cultured Cells
MDA-MB-435S cells from the American Type Culture
Collection were maintained in Dulbecco’s modified Eagle’s
medium (DMEM) containing 10% fetal bovine serum. Cells
seeded in 24 well dishes were transfected with siRNAs (200 nM)
using Oligofectamine (Invitrogen) according to the manufacturer’s
protocol. 24 hours later, the cells were detached using trypsin, and
replated in 12 well tissue culture dishes. In some cases, the cells
were retransfected the following day to ensure a high percentage of
the cells became transfected.
Figure 5. Injection of siRNA/oligofectamine complexes into mouse tumors inhibits tumor growth. MDA-MB-435S cells were implanted in
the mammary fat pad of SCID/NOD mice. Two days post-implantation, the mice were divided into 3 groups (one group of 10 control siRNA-injected
mice and two groups of 5 targeted siRNA mice) and the groups received twice weekly injections of either control, Src+STAT3, or Src+STAT3+Myc
siRNA into the site of the cell implantation/tumor. 47 days post-implantation, 5 mice in the control group were switched to Src+STAT3 siRNA
injections for the remainder of the experiment (Control, then Src+STAT3 group). Tumor growth was monitored and the results are shown (A), with
each treatment group shown in a single panel, and individual mouse tumors represented by connected data points. 126 days post-implantation, the
primary tumor(s) were excised (B) and weighed. The tumor weights for each mouse (data points) and the average tumor weight for each group
(horizontal bar) is shown (C). Tumor weight data was analyzed by Analysis of Variance and Tukey’s pairwise comparison, with significant differences
between the control group and two of the treatment groups noted ( *p,0.05).
doi:10.1371/journal.pone.0019309.g005
Inhibition of Tumor Growth Using siRNA
PLoS ONE | www.plosone.org 8 April 2011 | Volume 6 | Issue 4 | e19309Cell lysis, immunoblotting of proteins, and measurement
of kinase activity
Cells were lysed using RIPA buffer and processed for
immunoblotting [57] or kinase activity [58] as previously
described.
Cell Growth and Soft agar colony forming assay
Cells to be grown as monolayers were replated into 10 cm tissue
culture dishes in 2.5% fetal bovine serum/2.5% calf serum in
DMEM at a density of 1.5610
5 cells/dish. The medium was
changed once 3 days after plating and the cell number was
quantitated using a Beckman Z1 Particle Counter 5 days after
plating. Cells for soft agar assays were suspended at a density of
2.35610
4 cells/dish in soft agar and treated as previously
described [57]. Images of the plates were made using a Microtek
scanner. Statistical analysis of data was performed using Tukey’s
multiple comparison test and unpaired t-tests.
Figure 6. Injection of siRNA/oligofectamine complexes into
mouse tumors inhibits tumor metastasis. Mice treated in fig. 5 were
examinedgrosslyandmicroscopicallyforthepresenceoftumormetastasis
and representative pictures (A) (tumors indicated with yellow outline and
arrows) are shown. A summary of results from gross and microscopic
examination was compiled (B) with the presence to metastatic tumor
growth indicated (+).
doi:10.1371/journal.pone.0019309.g006
Figure 7. Src siRNA causes apoptosis of MDA-MB-435S cells.
MDA-MB-435S cells were transfected with siRNA or treated with 1 uM
staurosporine. 48 hours post-treatment, the cells were collected and
assayed for apoptosis using the TUNEL assay. Results are expressed with
log(fluorescence) on the horizontal axis and cell counts on the vertical
axis and is representative of triplicate experiments.
doi:10.1371/journal.pone.0019309.g007
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Labeling (TUNEL) Assay
Cells were detached using trypsin, washed twice with phosphate
buffered saline (PBS), and fixed for 20 min. in 1.5% paraformal-
dehyde in PBS at 4uC with gentle mixing. The cells were then
washed twice with PBS, suspended in 70% ethanol at 4uC, and
stored at 220uC until assayed. When assayed, the cells were
washed twice with PBS and then resuspended in 50 ml of Tunel
assay buffer consisting of 100 mM potassium cacodylate (pH 7.2),
2 mM CoCl2, 0.2 mM dithiotheitol, 3.3 nM fluorescein-conjugat-
ed dUTP, 13 nM dATP and 11 units of terminal deoxynucleotidyl
transferase for 90 minutes at 37uC. The cells were then washed
twice with PBS and analyzed by FACS sorting
Tumor Formation in NOD/SCID Mice
1610
6 cells were implanted by injection into the mammary fat
pad of 5–7 week old NOD/SCID mice (Jackson Laboratory). In
some experiments (as noted), the cells were initially transfected
with control siRNA, Src+STAT3 siRNAs, or Src+STAT3+cMyc
siRNAs. The cells were then detached and resuspended in 100 ml
phenol red-free DMEM/PBS (50/50) for implantation. In some
experiments, the mice also received twice weekly injections of
siRNA complexed with Oligofectamine into the tumor, or into the
site of tumor implantation (prior to appearance of a visible tumor).
Each siRNA injection consisted of 1.2 nmoles of siRNA (approx.
0.8 mg/kg) complexed with 13 ml of Oligofectamine in a final
volume of 110 ml of Optimem I medium (Invitrogen). Tumor
diameters were measured every 3–4 days using calipers and the
measurements were converted to tumor volumes using the formula
for a sphere. At the end of the experiment, tumors were excised,
weighed, and the data analyzed using Tukey’s multiple compar-
ison tests and unpaired t-tests.
Tissue fixation, sectioning, and staining
Tumor or tissue samples were fixed in phosphate-buffered 4%
formaldehyde and processed by standard histological methods.
5 mm paraffin sections were stained with hematoxylin and eosin
or were subjected to immunostaining with anti-GFP antibody.
Briefly, sections were deparaffinized and treated with Target
Retrieval Solution (Dako) according to the manufacturer’s
protocol. The sections were then stained using a Dakocytomation
Autostainer (Model LV-1) using a 1:600 dilution of anti-GFP
antibody (Santa Cruz). The staining was visualized using hor-
seradish peroxidase-conjugated goat anti-rabbit antibody, followed
by 3,3-diaminobenzidine. Counterstaining was with Mayer’s
Hematoxylin and Bluing solution (Harleco).
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